IP Library Patent Application 14689923
Patent Application
App. No. 14/689,923

Use of a Neuregulin to Treat Peripheral Nerve Injury

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
14/689,923
Abstract

Embodiments of the invention are directed to use of neuregulins to prevent or treat peripheral nerve injury, to attenuate, ameliorate or avoid the loss of peripheral nerve function.

Claims (12)

1 . A method of preventing or treating a peripheral nerve injury comprising administering an effective amount of a neuregulin to a subject at risk of suffering a peripheral nerve injury or to a subject having an existing peripheral nerve injury.

2 . The method of claim 1 , wherein the neuregulin is administered prior to a surgical procedure.

3 . The method of claim 1 , wherein the surgical procedure is a prostate cancer surgery.

4 . The method of claim 3 , wherein the prostate cancer surgery is a prostatectomy.

5 . The method of claim 1 , wherein neuregulin is administered to an expectant mother prior to delivery of an infant.

6 . The method of claim 1 , wherein neuregulin is administered to a patient prior to a treatment for breast cancer.

7 . The method of claim 4 , wherein the treatment for breast cancer is a complete or partial mastectomy.

8 . A method of treating or prophylaxing an erectile dysfunction resulting from peripheral nerve injury, comprising administering an effective amount of neuregulin to a subject having a peripheral nerve injury resulting in erectile dysfunction or a subject at risk of suffering such a peripheral nerve injury, respectively.

9 . A method of diagnosing the etiology of erectile dysfunction in a patient, said method comprising steps of:

administering an effective amount of neuregulin to a patient having an erectile impairment; and thereafter,

identifying if the erectile dysfunction lessens;

whereby, if there is a lessening of the erectile dysfunction following the administering step, the patient is diagnosed as having erectile dysfunction consequent to peripheral nerve damage.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded May 31, 2017
From: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: NEURONEX, INC.; CIVITAS THERAPEUTICS, INC.; ACORDA THERAPEUTICS, INC.
Reel/Frame 042643/0878 →
SECURITY INTEREST Recorded Jun 10, 2016
From: ACORDA THERAPEUTICS, INC.; CIVITAS THERAPEUTICS, INC.; NEURONEX, INC.
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 038950/0436 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 8, 2015
From: CAGGIANO, ANTHONY O.; BELLA, ANTHONY J.; IACI, JENNIFER F.
To: ACORDA THERAPEUTICS, INC.
Reel/Frame 035595/0091 →